Drug Trial Radar · NCT03333343
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
105
Actual
Start
Jan 29, 2018
Primary completion
Jul 12, 2027
Study completion Jul 12, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).
Conditions
- EGFR-mutant Non-small Cell Lung Cancer
Interventions
EGF816Drug
Study Drug
trametinibDrug
Study Drug
ribociclibDrug
Study Drug
LXH254Drug
Study Drug
INC280Drug
Study Drug
gefitinibDrug
Study Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events and serious adverse eventsTime frame: Every day until study end, approximately 4 years
- Number of participants with DLTs in the first cycle of combination (Dose escalation only)Time frame: 28 days
- Number of participants with dose interruptions and reductionsTime frame: From first dose until study ends, approximately 4 years
- Dose intensity of study drugsTime frame: From first dose until study ends, approximately 4 years
- ORR2Time frame: Every 8-12 weeks until study ends, approximately 4 years
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Tainan, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.